Results 201 to 210 of about 61,990 (306)

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Gut microbiota as a novel therapeutic target for eating disorders and obesity

open access: yesBritish Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė   +5 more
wiley   +1 more source

Re‐thinking peripheral dysfunctions in obesity: The emerging role of sulphaceutics and sulphanutraceutics

open access: yesBritish Journal of Pharmacology, EarlyView.
Obesity is a chronic, relapsing, multisystem disease in which cardiometabolic risk arises from excess adiposity and progressive dysfunction of peripheral organs, ultimately disrupting endocrine and metabolic crosstalk among tissues. Within this network, sulphur‐based biology, centred on hydrogen sulphide and related reactive sulphur species, has ...
Martina Smimmo   +4 more
wiley   +1 more source

The ongoing oleoylethanolamide story: Therapeutic implications in the control of obesity and its comorbidities

open access: yesBritish Journal of Pharmacology, EarlyView.
The global burden of obesity continues to rise, demanding effective pharmacological strategies for individuals in whom prevention alone is insufficient. Recent incretin‐based and multi‐agonist therapies have delivered unprecedented weight loss, demonstrating that the simultaneous modulation of multiple metabolic pathways can optimize body weight ...
Marzia Friuli   +6 more
wiley   +1 more source

Shared dysregulation of complement and phosphorylation pathways in the cerebrospinal fluid of encephalitis, Aicardi–Goutières syndrome, and autism

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
Abstract Aim To identify shared and disorder‐specific molecular alterations across encephalitis, Aicardi–Goutières syndrome (AGS), and autism spectrum disorder (ASD) using cerebrospinal fluid (CSF) proteomics. Method In this cross‐sectional case–control study, mass‐spectrometry‐based proteomics was performed on archived CSF samples collected between ...
Omar H. Shadid   +8 more
wiley   +1 more source

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy